- Home
- NRXP vs IMUX Comparison
NRXP vs IMUX Comparison
Compare NRXP & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | IMUX |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 155.8M |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NRXP | IMUX |
|---|---|---|
| Price | $2.68 | $7.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $38.50 | ★ $43.09 |
| AVG Volume (30 Days) | ★ 537.4K | 415.4K |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.70 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,225,000.00 | N/A |
| Revenue This Year | $357.94 | N/A |
| Revenue Next Year | $1,507.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $0.51 |
| 52 Week High | $5.06 | $17.43 |
Technical Indicators
Market Signals| Indicator | NRXP | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 32.34 | 26.46 |
| Support Level | $1.68 | $0.83 |
| Resistance Level | $3.62 | $15.82 |
| Average True Range (ATR) | 0.13 | 0.67 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 35.40 | 15.06 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.